Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.
Barnett JM, Cadman A, Gor D, Dempsey M, Walters M, Candlin A, Tisdale M, Morley PJ, Owens IJ, Fenton RJ, Lewis AP, Claas EC, Rimmelzwaan GF, De Groot R, Osterhaus AD.
Barnett JM, et al. Among authors: tisdale m.
Antimicrob Agents Chemother. 2000 Jan;44(1):78-87. doi: 10.1128/AAC.44.1.78-87.2000.
Antimicrob Agents Chemother. 2000.
PMID: 10602727
Free PMC article.
Clinical Trial.